Eli Lilly and Company (LLY)

Interest coverage

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Earnings before interest and tax (EBIT) (ttm) US$ in thousands 4,962,800 6,096,400 7,191,400 8,123,700 7,040,500 6,573,900 7,669,100 6,632,000 7,138,000 6,878,900 6,560,800 7,069,500 6,495,200 7,132,200 7,330,100 7,381,300 7,589,500 6,790,200 6,776,600 6,621,400
Interest expense (ttm) US$ in thousands 179,600 317,800 442,400 562,700 485,900 431,700 388,600 349,500 331,600 329,000 331,100 336,800 339,700 347,500 353,500 354,900 359,600 366,300 384,100 406,700
Interest coverage 27.63 19.18 16.26 14.44 14.49 15.23 19.74 18.98 21.53 20.91 19.82 20.99 19.12 20.52 20.74 20.80 21.11 18.54 17.64 16.28

December 31, 2024 calculation

Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $4,962,800K ÷ $179,600K
= 27.63

The interest coverage ratio of Eli Lilly and Company has been relatively healthy and stable over the past few years based on the provided data. The ratio indicates the company's ability to meet its interest obligations from its earnings before interest and taxes (EBIT).

From March 31, 2020, to December 31, 2024, the interest coverage ratio has fluctuated within a range between approximately 14.44 to 27.63. This range generally suggests that Eli Lilly has sufficient earnings to cover its interest expenses comfortably.

The highest interest coverage ratio was observed on December 31, 2024, at 27.63, indicating a strong ability to meet interest payments. However, there was a decrease in the ratio in the following quarters, reaching a low of 14.49 on December 31, 2023. This drop may signal a potential challenge in meeting interest obligations from earnings, although the ratio improved in subsequent periods.

Overall, Eli Lilly and Company's interest coverage ratios demonstrate a consistent ability to cover interest expenses with its operating income, reflecting financial stability and management's effective handling of debt obligations.


See also:

Eli Lilly and Company Interest Coverage (Quarterly Data)